Ameren Corp. (AEE) Financials Nov 17, 2014, 4:26
Ameren Corp. (AEE) Financials Nov 17, 2014, 4:26 p.m.
Income Statement Balance Sheet Cash Flow Statement
Annual Financials for Ameren Corp.
Fiscal year is January-December. All values USD millions. 2009 2010 2011 2012 2013 5-year trend
Sales/Revenue 7.21B 7.64B 7.54B 6.81B 5.84B
Cost of Goods Sold (COGS) incl. D&A 5.32B 5.69B 5.71B 5B 4.2B
COGS excluding D&A 4.52B 4.86B 4.9B 4.14B 3.42B
Depreciation & Amortization Expense 801M 837M 808M 858M 777M
Depreciation 724M 762M 741M 775M -
Amortization of Intangibles 53M 54M 61M 83M -
Gross Income 1.89B 1.95B 1.83B 1.81B 1.64B
2009 2010 2011 2012 2013 5-year trend
SG&A Expense - - - 0 0
Research & Development - - - 0 0
Other SG&A - - - 0 0
Other Operating Expense 412M 449M 457M 468M 458M
Unusual Expense (39M) 571M 136M 2.59B (1M)
EBIT after Unusual Expense 39M (571M) (136M) (2.59B) 1M
Non Operating Income/Expense (83M) 10M 19M 11M 13M
Non-Operating Interest Income 30M 33M 32M 33M 30M
Equity in Affiliates (Pretax) - - - 0 -
Interest Expense 508M 497M 451M 447M 398M
Gross Interest Expense 508M 497M 451M 447M 398M
Interest Capitalized 0 0 0 0 0
Pretax Income 956M 476M 836M (1.65B) 829M
Income Tax 332M 325M 310M (680M) 311M
Income Tax - Current Domestic (79M) 15M (39M) 34M (99M)
Income Tax - Current Foreign - - - - -
Income Tax - Deferred Domestic 411M 310M 349M (707M) 416M
Income Tax - Deferred Foreign - - - - -
Income Tax Credits - - - 7M 6M
Equity in Affiliates - - - 0 -
Other After Tax Income (Expense) 0 0 0 0 0
Consolidated Net Income 624M 151M 526M (974M) 518M
Minority Interest Expense 12M 12M 7M 0 6M
Net Income 612M 139M 519M (974M) 512M
Extraordinaries & Discontinued Operations 0 0 0 0 (223M)
Extra Items & Gain/Loss Sale Of Assets 0 0 0 0 0
Cumulative Effect - Accounting Chg 0 0 0 0 0
Discontinued Operations 0 0 0 0 (223M)
Net Income After Extraordinaries 612M 139M 519M (974M) 289M
Preferred Dividends 0 0 0 0 0
Net Income Available to Common 612M 139M 519M (974M) 512M
EPS (Basic) 2.78 0.58 2.15 (4.01) 1.19
Basic Shares Outstanding 220.4M 238.8M 241.5M 242.6M 242.6M
EPS (Diluted) 2.78 0.58 2.15 (4.01) 1.18
Diluted Shares Outstanding 220.4M 238.8M 241.5M 242.6M 244.5M
EBITDA 2.28B 2.34B 2.18B 2.2B 1.96B
Copyright 2014 FactSet Research Systems Inc. All rights reserved. Source FactSet Fundamentals.
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Trailblazer in Dermatology Recognized Again Fancy yourself a star in dermatology? Well, take notes from Dr. Monib A. Zirvi. The guy just got his due recognition from Marquis Who's Who for his sizable contributions to dermatology and research. For someone who's been at this game for over two decades, Zirvi doesn't just glide by on old merits. He's the real deal, and his...
Continue Reading
Seeing Patterns in Crisis: Jackson and Flint When Jackson, Mississippi's latest water crisis hit the news, it wasn't the first time folks were left high and dry. No, this fiasco's got deep roots, and it resonates with another infamous case: Flint, Michigan. In Maya Rockeymoore Cummings' book, RAGEism, these are badge-worthy examples of 'Resource Hoarding' where government...
Continue Reading
Breaking Ground in Tech Deployment The march toward commercializing new tech can be a nightmare. Ask any innovator trying to leap from lab genius to market ready, and they'll tell you the pathway is paved with hurdles—especially in the rough-and-tumble world of energy and industrial tech. RTI International's latest $14 million move? That's a massive step in leveling the...
Continue Reading
Trust in AI for Financial Guidance: Where Are We Headed? The market winds shift with every sunrise, and today’s buzzword? Artificial Intelligence. You’d almost think AI’s trying to steal my job along with every other trader’s mojo. But here's the twist—A survey from Possible Finance shows about 15% of folks would actually lean on AI for their financial advice....
Continue Reading
Unpacking Cove Capital's Latest Victory Cove Capital Investments has pulled off another coup, raising a hefty $9,964,510 for its Cove Essential Net Lease Industrial 108 DST. It's a Regulation D, Rule 506(c) offering, now fully subscribed, spotlighting a debt-free investment ethos and a rock-solid logistics site in Anchorage, Alaska. Strategic Facility Anchoring Investment...
Continue Reading
Maurices' Bold Financial Maneuver When a retailer like Maurices, with its near-century-long history, decides to play in the financial arena, it sure makes my ears perk up. This Duluth-based women's fashion retailer isn't just dipping its toes in—it's executing a full-blown refinancing blitzkrieg and coming out stronger. Announcing the completion of its refinancing plan...
Continue Reading
Pressure Builds for EquipmentShare Investors If you've thrown some cash into EquipmentShare.com Inc. (NASDAQ: EQPT), it's time to sit up and pay attention. There's smoke on the horizon, and Faruqi & Faruqi, LLP is waving the flag. They've got a securities class action spinning fast, and if you've suffered any losses, September 21, 2026, is a date you don't want to forget....
Continue Reading
Industry Gears Up for Financial Action Clearly, cannabis businesses are shouting louder than a vendor at a ballgame, demanding more than just the basic chips-and-soda banking service. They’re on the hunt for serious credit facilities, payments, and the traditional financial tools that most sectors take for granted. I mean, check this out: Shield Compliance just dropped...
Continue Reading
What's New in Travel Tech: Atli's Debut Wandering the globe might sound romantic until you realize your phone's a paperweight without the right data. Enter Atli, a shiny new AI-powered travel eSIM service, snugged right into your WhatsApp. This marvel comes from the folks at XForge Mobile and aims to obliterate the hassle of getting connected abroad. You know those...
Continue Reading
AbbVie's Game-Changing Atogepant Study When it comes to pushing boundaries in the pharmaceutical world, there's no sitting on the fence. AbbVie's Phase 3 LUNA study results are painting a bright picture for women who suffer from the relentless grip of menstrual migraines. In a world where not a single treatment option has been approved specifically for this condition,...
Continue Reading
Top 5 Most Recently Viewed Articles
Understanding the Proposed Mergers by PIMCO Canada PIMCO Canada Corp. recently announced exciting plans regarding the mergers of several closed-end funds. The proposed mergers, which involve the PIMCO Tactical Income Fund, PIMCO Tactical Income Opportunities Fund, and PIMCO Multi-Sector Income Fund, aim to create a new consolidated fund called the PIMCO Monthly Enhanced...
Continue Reading
Riding the Sodium Reduction Wave Alright, folks, let's chew the fat about this sodium reduction ingredient market. It’s looking like it's gonna swell from $6.3 billion in 2026 to a whopping $11.5 billion by 2036. That's a steady 6.2% annual clip. We've got health-conscious consumers and government regulations kicking the demand for sodium reduction solutions into high...
Continue Reading
Evercore ISI Maintains Positive Outlook on Microsoft Stock Recently, Evercore ISI expressed confidence in Microsoft Corporation (NASDAQ: MSFT) by retaining its Outperform rating and an ambitious price target of $500.00. The firm stands by the company’s robust fundamentals, even amidst a slight slowdown in stock performance compared to the S&P 500 index. Understanding...
Continue Reading
Hess CEO Shares Positive Outlook for Oil Demand John Hess, the CEO of Hess Corporation (NYSE: HES), recently expressed an optimistic perspective on the oil market during his presentation at a leading energy conference. He believes that the market is moving towards a balance rather than facing oversupply, despite concerns regarding demand from certain regions and...
Continue Reading
CorMedix Inc. Shows Promising Financial Growth in Q3 In a recent financial results conference call, CorMedix Inc. (NYSE American: CRMD) unveiled a significant achievement in the third quarter of 2024, with net revenue soaring to $11.5 million. This growth was primarily fueled by the successful launch and ongoing rollout of its flagship product, DefenCath. The company has...
Continue Reading